Skip to content
Intrinsic value · Buy/Sell verdict · scores — free· 1403 Nifty 500 stocks· EOD 2026-06-19

Albert David Limited

ALBERTDAVD · NSE · Healthcare

₹711.15
-0.75 (-0.11%)
Fair valueHold
The bottom line

StocksWizard rates Albert David Limited a Hold, scoring 50/100 on our blended model. At ₹711.15 it trades below our blended DCF and relative-multiples fair value of ₹1,422.3, implying roughly 100% upside to that estimate — we read the stock as undervalued by 100%. Financial health scores 70/100 (grade B), in the safe band on the Altman Z-score, with a Piotroski F-score of 2/9. It clears 6 of 12 investability checks, with durability 32, valuation 45 and momentum 30 on our 0–100 scales.

These are StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.

Our verdict
Hold50/100
Quality32
Valuation73
Momentum30
Financial trend62
Intrinsic value
Our fair value
₹1,422.3
Undervalued by 100%
Price ₹711.15Range ₹1,308.52₹1,536.08

With a 20% margin of safety, our buy-below price is ₹1,137.84. Low-confidence estimate — limited data.

B
Financial health 70/100
Altman Z 3.8 · Safe zone

Piotroski F-score 2/9 — quality of earnings & balance sheet.

Investability checklist

Passed 6 of 12 checks50/100
  • ROE above 15%-0.4%
  • Low debt (D/E < 0.5)0.08x
  • Positive free cash flow
  • Revenue growth > 10%15%
  • Earnings growing
  • Net margin ≥ 10%-0.4%
  • Current ratio > 1.53.24
  • Below our fair value
  • Margin of safety ≥ 20%
  • Above 200-day average
  • Above 50-day average
  • Positive 1-year return
  • Altman Z in safe zoneZ 3.8
  • Piotroski ≥ 72/9

1-year price

EOD · 2026-06-19
1W
-2.0%
1M
+0.7%
3M
+6.2%
6M
-7.7%
1Y

Our scores

Durability32
Valuation45
Momentum30

Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.

Quarterly results

4Q2019₹80 Cr revenue
Net profit ₹5 Cr7% margin
1Q2020₹60 Cr revenue
Net profit ₹-3 Cr-5% margin
Revenue Net profitLatest revenue QoQ -25%

Annual financials

2019₹324 Cr revenue
Net profit ₹0 Cr0% margin
2020₹321 Cr revenue
Net profit ₹19 Cr6% margin
Revenue Net profitLatest revenue YoY -1%

Shareholding

Promoter64.0%
Institutions1.6%
Public & other34.3%

Promoter holding via insider stake; institutional via reported holdings.

Key fundamentals

Market cap
₹406 Cr
P/E ratio
P/B ratio
1.04
EPS (TTM)
₹-2.64
ROE
-0.4%
Debt / Equity
0.08x
Profit margin
-0.4%
Free cash flow
₹-37 Cr
52-week high
₹941.36
-24.46% from high
52-week low
₹587.05
Dividend yield
0.7%
Beta
0.24

SWOT snapshot

Strengths

  • Lightly leveraged balance sheet.
  • Financially solid — Altman Z 3.8.

Weaknesses

  • Low return on equity (-0.4%).
  • Price below its 200-day moving average (downtrend).
  • Weak Piotroski score (2/9).

Opportunities

  • Revenue growing (15% YoY).
  • Trades ~100% below our estimated fair value.

About Albert David Limited

Albert David Limited manufactures and trades in pharmaceutical formulations, infusion solutions, herbal dosage forms, and bulk drugs in India and internationally. It offers formulations for parenterals, oral/enterals, topical agents, aerosol, gynecology therapy, orthopedic, and vision care products. Albert David Limited was incorporated in 1938 and is headquartered in Kolkata, India.

More in Healthcare

All stocks

Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.